Analyst Price Targets — FGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2023 2:00 am | Annabel Samimy | Stifel Nicolaus | $28.00 | $17.32 | StreetInsider | Stifel Upgrades FibroGen (FGEN) to Buy |
Latest News for FGEN
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) from the investigator-sponsored Phase 1b/2 study will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FGEN.
U.S. House Trading
No House trades found for FGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.